Search
Aftobetin
go.drugbank.com/drugs/DB20425InvestigationalAftobetin is under investigation in clinical trial NCT02928211 (Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations).
Taragarestrant
go.drugbank.com/drugs/DB21574InvestigationalTaragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).
CERE-120
go.drugbank.com/drugs/DB05637InvestigationalCERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor.
ARG201
go.drugbank.com/drugs/DB06621ExperimentalARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc).
Tepoxalin
go.drugbank.com/drugs/DB11466ExperimentalVet approvedIt is primarily used to reduce inflammation and relief of pain caused by musculoskeletal disorders such as hip dysplasia and arthritis.
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781InvestigationalHu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated
Escin
go.drugbank.com/drugs/DB15907InvestigationalSodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalSIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.
Palmidrol
go.drugbank.com/drugs/DB14043InvestigationalNutraceuticalA cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection.
Cetrelimab
go.drugbank.com/drugs/DB15421InvestigationalCetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD